Chiome Bioscience Inc. [4583.T]
TOKYO, May 14 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) reported a revenue increase of ¥147 million for the quarter ending December 2025, up from ¥138 million in the same period last year.
Operating expenses decreased by ¥23 million, primarily due to reduced clinical development costs. The company also noted progress in its pipeline, including completing patient enrollment for liver cancer and melanoma trials and advancing pediatric cancer research. In the biopharmaceutical support services sector, Chiome recorded revenues of ¥147 million, marking an 8% growth compared to the previous year.
Key partnerships continued to drive this performance, with ongoing collaborations with major pharmaceutical companies such as Chugai Pharmaceutical, Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical. Additionally, the company received patent examination notifications related to its European projects and advanced discussions on potential new partnerships. Looking ahead, Chiome plans to leverage its antibody manufacturing technology platform to expand its integrated drug discovery (IDD) business, aiming to create sustainable growth through a three-layer portfolio strategy encompassing high-risk, medium-risk, and low-risk ventures.
This approach includes developing proprietary pipelines, providing research support services, and fostering IDD collaborations to ensure stable cash flow and future profitability.
🟢 Confidence: High AI-translated content.